Immunotherapy in the resectable NSCLC setting: learnings from patient cases

Live webinar from ESMO in Madrid


Sunday 22nd October
20:00 - 21:30

Immunotherapy (in combination or as monotherapy) has gained a lot of importance in the treatment of metastatic non-small cell lung cancer (NSCLC) patients, and has even become the standard of care for most if not all of them. More recent data and developments have now also brought immunotherapy to earlier stages of the disease, amongst which the resectable NSCLC setting. This live webinar (and already the 8th edition of the ECLIPSE educational webinar series) will focus on sharing experiences with immunotherapy in this resectable NSCLC setting from both the pneumo-oncologist AND thoracic surgeon’s perspective. Patient cases will be presented and there will be room for Q&A and a panel discussion with the experts towards the end of the meeting.


Welcome

What does resectability mean in NSCLC?

Dr. Mariana Brandao, Institut Bordet Belgium

Neo-adjuvant IO+chemo, the pneumo-oncologist’s perspective

Prof. Dr. Nicolas Girard, Curie Institute France

Neo-adjuvant IO+chemo, the thoracic surgeon’s perspective

Prof. Dr. Jonathan Spicer, McGill Health Center Canada

Expert panel discussion

All








© 2023 Copyright Bristol Myers Squibb AB
SEPTEMBER 2023 ONC-SE-2300086

Du kan kontakta vår EU Data Protection Officer på mailadressen EUDPO@BMS.com för att utöva dina rättigheter knutna till integriteten av dina personuppgifter, liksom att ta upp problem eller frågor i relation till hanteringen av din personuppgifter av Bristol Myers Squibb Company

Allmänna vilkor    Integritetspolicy    Biverkningar/Reklamationer    Användning av kakor    Kontakta oss